🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Bemarituzumab

    Amgen

    Solid tumours

    phase 2 small molecule active

    1 trial

  2. Bemarituzumab + Flot regimen

    United Therapeutics Europe Ltd

    Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas

    phase 2 small molecule terminated

    1 trial

  3. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo of belimumab

    Pari Pharma GmbH

    Cryoglobulinemia vasculitis

    phase 2 small molecule active

    1 trial

  4. Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  5. Bexarotene 1% gel

    LIGAND PHARMACEUTICALS INC

    Parapsoriasis

    phase 2 small molecule terminated

    1 trial

  6. Bezuclastinib Tablets (Formulation A)

    Cogent Biosciences

    SSM

    phase 2 small molecule active

    1 trial

  7. Bezuclastinib in combination with sunitinib

    Cogent Biosciences

    Gastrointestinal Stromal Tumors

    phase 2 small molecule active

    1 trial

  8. Bleomycin medac, 15 000 RÜ süstelahuse pulber

    The George Institute

    VASCULAR MALFORMATION

    phase 2 small molecule active

    1 trial

  9. Blinatumomab

    Amgen

    B Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  10. Blinatumomab

    Takeda

    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

    phase 2 mab active

    1 trial

  11. Blinatumomab SC2

    Amgen

    Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  12. Bortezomib

    Takeda

    Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

    phase 2 small molecule completed

    1 trial

  13. Braftovi 75 mg hard capsules, LIBTAYO 350 mg concentrate for solution for infusion., Mektovi 15 mg film-coated tablets, Fianlimab, Braftovi 50 mg hard capsules

    Disc Medicine

    Melanoma

    phase 2 small molecule active

    1 trial

  14. Brentuximab Vedotin

    United Therapeutics Europe Ltd

    Ann Arbor Stage IB Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  15. Brigatinib

    Takeda

    Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma

    phase 2 small molecule terminated

    1 trial

  16. Brigatinib

    Takeda

    NSCLC, Stage III

    phase 2 small molecule terminated

    1 trial

  17. Brigatinib

    Takeda

    Anaplastic Large Cell Lymphoma, ALK-Positive

    phase 2 small molecule active

    1 trial

  18. Brigatinib

    Takeda

    Lymphoma, Large-Cell, Anaplastic

    phase 2 small molecule completed

    1 trial

  19. Budenofalk 3mg magensaftresistente Hartkapseln, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infu

    Hoffmann-La Roche

    Untreated Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  20. Budenofalk 4 mg Zäpfchen, placebo to test

    Dr. Falk Pharma GmbH

    Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma

    phase 2 small molecule active

    1 trial

  21. BufferGel

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 small molecule completed

    1 trial

  22. Busulfan 6 mg/ml concentrate for solution for infusion, THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion, Fludarabine Accord Healthcare 25 mg/ml solution à diluer pour solution injectable /pour perfusion

    The George Institute

    High-risk myeloïd malignancies

    phase 2 small molecule active

    1 trial

  23. Busulfan Koanaa 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GRANOCYTE 34 Millions UI/ml, poudre et solvant pour solution injectable / perfusion, Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene, Plerixafor Accord 20 mg/ml solution for injection

    Fondazione Telethon ETS

    transfusion-dependent beta-thalassemia

    phase 2 small molecule active

    1 trial

  24. Byetta 10 micrograms solution for injection in pre-filled pen

    The George Institute

    Hypopituarism

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources